A Prospective Observational Study of the Efficacy of Neoadjuvant Chemotherapy in Newly Diagnosed Inoperable Patients of Epithelial Ovarian Cancer
International Research Journal of Oncology,
Introduction: Ovarian cancer is the leading cause of death from gynecological cancers in developed countries. More than 70% of patients have Stage III – IV disease at diagnosis. The standard of care for advanced ovarian cancer is primary debulking surgery (PDS) followed by adjuvant (ADJ) chemotherapy. There are very few prospective randomized Indian studies that have evaluated the effectiveness of neoadjuvant chemotherapy (NACT) in advanced ovarian cancer. This study attempted to evaluate the efficacy of NACT in advanced epithelial ovarian cancer patients who were unfit for upfront surgery.
Methods: This was a prospective observational study involving newly diagnosed patients with inoperable epithelial ovarian cancer, conducted over a period of 18 months from October 2016 to March 2018 at the department of Medical Oncology at a tertiary care oncology center, situated in Hyderabad, India. Detailed clinical history, laboratory reports, imaging and histopathological reports were obtained and maintained in a standard proforma.
Results: The median age at presentation was 51 years with a range of 37 to 70 years. 82.8% of the cases belonged to international federation of obstetrics and gynecology (FIGO) stage III. The objective response rate to NACT was 85.93% and the optimal cytoreduction rate was 85.96%. Post operative grade 3 or 4 adverse events were observed in 19.3% of the patients.
Conclusion: Neoadjuvant chemotherapy is an alternative approach to primary debulking surgery for advanced ovarian cancers. Among inoperable advanced epithelial ovarian cancer patients, neoadjuvant chemotherapy is associated with good objective response rates. Patients undergoing interval debulking surgery following neoadjuvant chemotherapy had less peri-operative morbidity and mortality.
- Epithelial ovarian cancer
- neoadjuvant chemotherapy
- optimal cytoreductive surgery
- interval debulking surgery
How to Cite
Wright JD, Herzog TJ, Powell MA, et al. Morbidity of cytoreductive surgery in the elderly. Am J ObstetGynecol. 2004;190:1398-400.
Hoskins WJ, Mcguire WP, Brady MF, Homesley HD, Creasman WT, BermanM, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J ObstetGynecol. 1994;170:974-80.
Shekarsharma, Vijaykumar DK, Cjitrathara K, et al. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A Retrospective study. Ind j med and pedia oncol. 2007;28(1):7-13.
Guidozzi F, Ball JH, et al. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. GynecolOncol. 1994;53:326-30.
Shimada M, Kigawa J, Minagawa Y, Irie T, Takahashi M, Terakawa N, et al. Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. Am J ClinOncol. 1999;22:481-4.
Anna Fagotti, Gabriella Ferrandina, Giuseppe Vizzielli, et al. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapyy in advanced epithelial ovarian cancer(SCORPION trial). Europen journal of cancer. 2016;59:22-33.
Upsana Baruah, Debabrata Barmon, Amal Chandra Kataki, et al. Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study: Ind j of med. And pediaoncol. 2015;36(1):38-42.
Deo SVS, Goyal H, et al. Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced ovarian cancer. Indian J Cancer. 2006;43(3):117-21.
Sean Kehoe, Jane Hook, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet Oncol. 2015;386: 249-257.
Chan JK, Brady MF, Penson RT, et al. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med. 2016;374(8):738-48.
Abstract View: 237 times
PDF Download: 106 times